Ovarian Club X and CoGEN in Asia

SpeakerS

Sijia LU (China)

Dr. Sijia Lu is the co-inventor of MALBACTM (Multiple Annealing and Looping Based Amplification Cycles) technology and co-founder of Yikon Genomics Co., Ltd. With 4 international and 12 national patents, Dr. Lu has extensive experiences in the development and application of single-cell whole genome amplification (WGA) technology. Dr. Lu’s work has been published in many top-tier journals, including Science and Cell, and cited more than 2000 times world-wide. Under his leadership, Yikon Genomics has developed a series of unique technical platforms that have been successfully used for single-cell whole genome sequencing, preimplantation genetic screening, preimplantation genetic diagnosis, prenatal genetic testing and cancer diagnosis. Dr. Lu has received many national and international awards in recognition of his significant contribution to the field.

Education 

Bachelor of Science Department of Physics, Fudan University 2003-2007
Ph.D.  Department of Chemistry and Chemical Biology, Harvard University 2007-2012

Experiences

Chief Executive Officer Yikon Genomics Co., Ltd.  2016-Present
Chief Technology Officer Yikon Genomics Co., Ltd. 2012-2015
Research Associate Department of Chemistry and Chemical Biology, Harvard University, USA 2007-2012

Selected Awards

6th “Jiangsu Province Youth Friendship Envoy” 2016
12th “The Six Talents Summit” High-level Professionals 2016
High-level Innovation and Entrepreneurship Talent Fellowship  2014
Core Member, High-level Innovation and Entrepreneurship Team Fellowship  2013
Jiangsu Province “113 Talents” Award 2013
Harvard Merit PhD Fellowship 2011
National Outstanding International Student Scholarship 2010

Membership   

Member, China Youth Returnee Association 2015-present
Member, American Society of Reproductive Medicine  2014-present
Member, Genetics Society of America 2010-2012
Member, The Optical Society of America 2007-2010

Abstract

The Development and Clinical Studies of Non-invasive Chromosomal Screening (NICS)

Objective: Conventional preimplantation genetic screening (PGS) involves the blastomere or trophectoderm biopsy from embryos at an early developmental stage. These procedures are invasive, technically challenging and may affect the development of embryos. Recently, a new NICS (Non-invasive Chromosomal Screening) assay based on the MALBAC (Multiple Annealing and Looping Based Amplification Cycles) technology has been developed, which allows the detection of chromosomal abnormalities of in vitro fertilized embryos without embryo biopsy. The present study is designed to evaluate the NICS assay in a clinical setting. DESIGN: A retrospective observational study from September 2015 to September 2016.

Materials and Methods: A total of 353 frozen-thawed single blastocyst transfer (SBT) cycles were divided into three groups with different blastocyst selection criteria: the first was the No-choice group which had only one blastocyst for transfer for each patient (n=285). The second was the Morphology group. The patients of this group had at least two blastocysts available and blastocysts were selected for single blastocyst transfer on the basis of traditional morphological assessments (n=41); the third was the NICS group that had at least two blastocysts for each patient and the euploid blastocysts were selected using NICS for single blastocyst transfer (n=27). RESULTS: The biochemical pregnancy rate in the No-choice group, the Morphology group and the NICS group was 65.3%, 65.9% and 85.2%, respectively (P=0.232). Among three groups, the NICS group had the highest implantation rate (63.0%) (P=0.193), compared with 56.1% and 45.3% in the Morphology group and the No-choice group, respectively. There was no incidence of early miscarriage in the NICS group, while the early miscarriage rate in the No-choice group and the Morphology group was 21.1% and 13.0%, respectively (P=0.094). A significant difference was found in the ongoing pregnancy rate among the three groups, which was highest in the NICS group (63.0%) and lowest in the No-choice group (37.9%) (P=0.016).

Conclusions: NICS is a novel genetic testing that allows an accurate selection of blastocysts with better developmental potential for transfer and might improve the clinical outcomes.